- Live video webcast interactive Q&A with participating companies -
/PRNewswire/ -- Evofem Biosciences, Inc., (OTCQB: EVFM) (the "Company") today announced that Saundra Pelletier, Chief Executive Officer and Amy Raskopf, Senior...
/PRNewswire/ -- Evofem Biosciences, Inc., (OTCQB: EVFM) today announced that Padagis Israel Pharmaceuticals Ltd. (Padagis) has withdrawn the Paragraph IV...
/PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) (Evofem or the "Company") today announced it has successfully negotiated and entered into a fourth...
/PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) (Evofem or the Company) today announced it has signed a confidential non-binding letter of intent (LOI)...
/PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) today announced financial results for the second quarter and first half of 2023....
/PRNewswire/ -- Evofem Biosciences, Inc., (OTCQB: EVFM) (the "Company") today announced that Saundra Pelletier, Chief Executive Officer, and Amy Raskopf,...
/PRNewswire/ -- Evofem Biosciences, Inc., (OTCQB: EVFM) (the "Company") today announced a 1-for-125 reverse stock split of the Company's common stock, which...
/PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM), the maker of Phexxi® (lactic acid, citric acid and potassium bitartrate), has reported financial...
/PRNewswire/ -- Evofem Biosciences, Inc., (OTCQB: EVFM), the maker of Phexxi® (lactic acid, citric acid and potassium bitartrate), today announced the...